Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
October 29, 2020 at 04:27 am
Share
Jiangsu Sihuan Bioengineering Co. Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 354.414 million compared to CNY 285.787 million a year ago. Operating income was CNY 29.622 million compared to CNY 15.698 million a year ago. Net income was CNY 21.751 million compared to CNY 9.478 million a year ago. Basic earnings per share from continuing operations was CNY 0.0211 compared to CNY 0.0092 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
